• Welcome! Sign In or Register

Spread The News

Log in or Register to rate this News Story
Be the first to rate this story!

Tweet

Forward to a Friend
Print This Story
Write a Comment

More Industry Headlines

Will the EU medical device approval process get tougher? Expert analyst talks about a new potential challenge for the industry.

Prior authorization schemes don't save taxpayers money Congressional Budget Office scores health care programs, including imaging.

Q&A with a U.S. Army biomed To celebrate Healthcare Technology Management Week, here's a story of one biomed's unique journey.

Maryland governor signs breast density law Maryland joins the growing list of states to enact density notification laws.

FDA approves radiopharmaceutical to treat advanced prostate cancer Radioactive therapeutic agent can spare healthy tissue.

GE Healthcare unveils technology for imaging metal implants First-time software can create clear images despite metal.

Monarch Medical PET Services removes CEO Gary Moyers named interim CEO.

Will the Angelina Jolie mastectomy test change cancer screening? The actress sheds awareness on new genetic screening tool for breast cancer.

What technologies should we be using for mammography? A new study fills in the gaps in digital breast mammography.

New contrast agent could last longer than traditional dyes Researchers say they have found a cheaper, more effective dye.

Hologic wraps up $3.8 billion Gen-Probe buy

Hologic said Wednesday that it wrapped up its nearly $3.8 billion cash purchase of molecular diagnostics company Gen-Probe Inc., in line with the company's earlier projections.

On an earnings call this week, the publicly traded women's health medical device company indicated that it expected the deal, first announced in April, to finish by Aug. 1.

Story Continues Below Advertisement

Ad Statistics

Times Displayed: 5169840
Times Visited: 3953

We want to buy your Siemens Symphony MRI -- today!

Top Dollar Paid, Fixed or Mobile. Call our Siemens Specialist for a Quote today -- 212-558-6600 Ext. 250

Gen-Probe, based in San Diego, makes tests for STDs and the West Nile Virus, among other conditions.

Gen-Probe's shareholders voted to approve the transaction on Tuesday. Shareholders will receive $82.75 in cash for each share.

Hologic expects the deal to add 20 cents to its adjusted earnings per share for the next fiscal year. The Bedford, Mass.-based company also hopes to realize $75 million in "cost synergies" over the next three years.

This week, while announcing third quarter financial results, Hologic also revealed that it was nearly halfway to its sales goal for its 3-D mammography system, the first of its kind cleared for sale in the United States.

Interested in Medical Industry News? Subscribe to DOTmed's weekly news email and always be informed. Click here, it takes just 30 seconds.